20 Feb 2023 • A dual sodium-glucose co-transporter and 1 inhibitor called Sotagliflozin is used to treat both type 2 (T2D) and type 1 (T1D) diabetes. Sotagliflozin inhibits intestinal SGLT-1 and renal sodium-glucose co-transporter 1 & 2, which slows down the absorption of glucose and lowers post-prandial glucose. Results from a phase 3 trial showed that Sotagliflozin 400 mg, but not 200 mg, significantly decreased HbA1c after 26 weeks in persons with type 2 diabetes (T2D) and stage 3 chronic kidney disease (CKD3) compared with placebo. In individuals with at least A2 albuminuria, the researchers also observed a decrease in urine albumin creatinine ratio (UACR) at 26 weeks with each of the two doses; however, the effects did not last at week 52. In 787 patients with type 2 diabetes and an estimated glomerular filtration rate of 30-59 mL/min/1.73 m2, the study assessed Sotagliflozin 200 and 400 mg. The main goal was to compare Sotagliflozin with a placebo for HbA1c reductions at week 26. Changes in various glycemic and renal endpoints globally and in CKD3 subgroups served as secondary endpoints. On February 13th, 2023, the study was published in the journal "Diabetes, Obesity and Metabolism".

Source: Medical Dialogues | Read full story